MX2015014282A - Terapia de combinación selectiva de tumor. - Google Patents

Terapia de combinación selectiva de tumor.

Info

Publication number
MX2015014282A
MX2015014282A MX2015014282A MX2015014282A MX2015014282A MX 2015014282 A MX2015014282 A MX 2015014282A MX 2015014282 A MX2015014282 A MX 2015014282A MX 2015014282 A MX2015014282 A MX 2015014282A MX 2015014282 A MX2015014282 A MX 2015014282A
Authority
MX
Mexico
Prior art keywords
tumor
combination therapy
selective combination
therapies described
treatment
Prior art date
Application number
MX2015014282A
Other languages
English (en)
Inventor
Paul J Hergenrother
David A Boothman
Josep S Bair
Lifen Cao
Jimming Gao
Xiumei Huang
Xiuquan Luo
Xinpeng Ma
Zachary R Moore
Elizabeth I Parkinson
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of MX2015014282A publication Critical patent/MX2015014282A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Las terapias descritas en la presente pueden ser selectivamente letales hacia una variedad de diferentes tipos de células de cáncer y condiciones de cáncer en un sujeto. Las terapias de combinación descritas en la presente, pueden ser útiles para el manejo, tratamiento, control o tratamiento adjunto de enfermedades, en donde la letalidad selectiva es benéfica en la terapia quimioterapéutica, en particular en donde la enfermedad está acompañada por niveles elevados de NQO1.
MX2015014282A 2013-04-09 2014-04-08 Terapia de combinación selectiva de tumor. MX2015014282A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361810008P 2013-04-09 2013-04-09
PCT/US2014/033400 WO2014168991A1 (en) 2013-04-09 2014-04-08 Tumor-selective combination therapy

Publications (1)

Publication Number Publication Date
MX2015014282A true MX2015014282A (es) 2016-07-20

Family

ID=51689971

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015014282A MX2015014282A (es) 2013-04-09 2014-04-08 Terapia de combinación selectiva de tumor.
MX2021000828A MX2021000828A (es) 2013-04-09 2015-10-09 Uso de farmacos bioactivables por nqo1 para mejorar la actividad inhibidora de parp1.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021000828A MX2021000828A (es) 2013-04-09 2015-10-09 Uso de farmacos bioactivables por nqo1 para mejorar la actividad inhibidora de parp1.

Country Status (15)

Country Link
US (2) US10272099B2 (es)
EP (1) EP2984184B1 (es)
JP (2) JP6615746B2 (es)
CN (2) CN111481551B (es)
AU (2) AU2014251043B2 (es)
BR (1) BR112015025662A2 (es)
CA (1) CA2909091C (es)
DK (1) DK2984184T3 (es)
ES (1) ES2853973T3 (es)
HU (1) HUE052930T2 (es)
MX (2) MX2015014282A (es)
PL (1) PL2984184T3 (es)
PT (1) PT2984184T (es)
WO (1) WO2014168991A1 (es)
ZA (1) ZA201507755B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111481551B (zh) * 2013-04-09 2023-06-09 伊利诺伊大学董事会 肿瘤选择性联合疗法
KR20190025646A (ko) * 2016-06-27 2019-03-11 시스템즈 온콜로지, 엘엘씨 병용 화학요법
WO2019113345A1 (en) * 2017-12-06 2019-06-13 Spyro Mousses Combination of cancer therapeutics for treatment of cancer and hyperproliferative diseases
WO2019156684A1 (en) * 2018-02-12 2019-08-15 Solugen, Inc. Hydrogen peroxide production method, system, and apparatus
CA3095709A1 (en) 2018-04-05 2019-10-10 Noviga Research Ab Novel combinations of a tubulin polymerization inhibitor and a poly (adp-ribose) polymerase (parp) inhibitor for use in the treatment of cancer
JP7447013B2 (ja) * 2018-04-09 2024-03-11 ユンジン ファーム．カンパニー、リミテッド １，２－ナフトキノン誘導体化合物を含む固形癌または血液癌の予防または治療用薬学組成物
CA3130513A1 (en) * 2019-03-18 2020-09-24 The Board Of Regents Of The University Of Texas System Tumor-selective combination therapy

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4906562A (en) * 1984-12-21 1990-03-06 Oncogen Monocolonal antibodies and antigen for human non-small cell lung carcinomas
ES2088822B1 (es) * 1994-02-24 1997-08-01 Univ Madrid Complutense Nuevos derivados antraquinonicos con actividad antitumoral y sus aplicaciones.
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
FR2797446B1 (fr) * 1999-08-13 2001-11-02 Lafon Labor Derives de phenanthroline-7-ones et leurs applications en therapeutique
US6635677B2 (en) * 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
JP2005501848A (ja) * 2001-08-15 2005-01-20 アイコス コーポレイション ２ｈ−フタラジン−１−オンおよびその使用方法
CN100566711C (zh) * 2002-04-15 2009-12-09 斯隆-凯特林癌症研究院 治疗癌症的化合物及其用途
US6890950B2 (en) * 2002-04-23 2005-05-10 Case Western Reserve University Lapachone delivery systems, compositions and uses related thereto
BRPI0408996A (pt) 2003-03-31 2006-03-28 Pfizer saia de inibidores tricìclicos de poli(adpp-ribose) polimerases
US8614228B2 (en) * 2004-08-11 2013-12-24 Arqule, Inc. Quinone prodrug compositions and methods of use
WO2006024545A1 (en) * 2004-09-03 2006-03-09 Stichting Voor De Technische Wetenschappen Fused bicyclic natural compounds and their use as inhibitors of parp and parp-mediated inflammatory processes
WO2007092963A1 (en) * 2006-02-09 2007-08-16 Spectrum Pharmaceuticals, Inc. Bladder cancer treatment involving determination of tumor enzyme level
EP2173333B1 (en) 2006-12-29 2018-06-27 Tracon Pharmaceuticals, Inc. Combinations of antifolate agent and methoxyamine in the treatment of cancer
JP2011503111A (ja) * 2007-11-12 2011-01-27 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ阻害剤単独又は抗腫瘍剤との組み合わせによる乳がんの治療
EP2250282A4 (en) 2008-02-04 2011-05-18 Bipar Sciences Inc METHOD FOR THE DIAGNOSIS AND TREATMENT OF PARP-MEDIATED DISEASES
KR20130044382A (ko) * 2010-03-01 2013-05-02 마이렉시스 인코포레이티드 화합물 및 그의 치료 용도
ES2602475T3 (es) * 2010-04-15 2017-02-21 Tracon Pharmaceuticals, Inc. Potenciación de la actividad anticáncer por terapia de combinación con inhibidores de la vía BER
US9081428B2 (en) * 2010-04-23 2015-07-14 Psion Inc. Apparatus and method for impact resistant touchscreen display module
CA2811015A1 (en) * 2010-09-15 2012-03-22 Almac Diagnostics Limited Molecular diagnostic test for cancer
TR201807363T4 (tr) * 2010-09-22 2018-06-21 Univ Texas Hedefleyici nqo1 i içeren kanser tedavi yöntemleri.
US20120142650A1 (en) * 2010-12-07 2012-06-07 John Hollingsworth Method for treating lung disease
US20120208767A1 (en) * 2011-02-14 2012-08-16 University Of Maryland, Baltimore Method to Detect or Treat Painful Bladder Syndrome based on Relation to Quinone Oxidoreductase 1
EP3219949B1 (en) * 2011-09-12 2019-03-20 Cummins Emission Solutions, Inc. A kit for installing an aftertreatment system package for exhaust gas
US9233960B2 (en) 2011-10-14 2016-01-12 The Board Of Trustees Of The University Of Illinois Compounds and anti-tumor NQO1 substrates
CN111481551B (zh) * 2013-04-09 2023-06-09 伊利诺伊大学董事会 肿瘤选择性联合疗法

Also Published As

Publication number Publication date
ZA201507755B (en) 2019-11-27
JP6615746B2 (ja) 2019-12-04
JP6719620B2 (ja) 2020-07-08
BR112015025662A2 (pt) 2017-07-18
US20180099002A1 (en) 2018-04-12
WO2014168991A1 (en) 2014-10-16
DK2984184T3 (da) 2021-03-01
PT2984184T (pt) 2021-02-24
EP2984184B1 (en) 2020-11-25
AU2014251043A1 (en) 2015-11-05
PL2984184T3 (pl) 2021-06-14
JP2016516775A (ja) 2016-06-09
CN111481551B (zh) 2023-06-09
JP2019163309A (ja) 2019-09-26
US10576096B2 (en) 2020-03-03
EP2984184A4 (en) 2016-11-30
ES2853973T3 (es) 2021-09-20
HUE052930T2 (hu) 2021-05-28
CA2909091C (en) 2021-11-02
CN105658809A (zh) 2016-06-08
CA2909091A1 (en) 2014-10-16
CN105658809B (zh) 2020-03-27
CN111481551A (zh) 2020-08-04
AU2014251043B2 (en) 2020-01-16
US20160030457A1 (en) 2016-02-04
US10272099B2 (en) 2019-04-30
MX2021000828A (es) 2021-03-25
AU2020202453B2 (en) 2022-04-14
AU2020202453A1 (en) 2020-05-28
EP2984184A1 (en) 2016-02-17

Similar Documents

Publication Publication Date Title
MX2021000828A (es) Uso de farmacos bioactivables por nqo1 para mejorar la actividad inhibidora de parp1.
PH12016500840A1 (en) Methods of using interleukin-10 for treating diseases and disorders
PH12016500582A1 (en) Heterocyclic compounds and uses thereof
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
MX2020011772A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
BR112015021423A2 (pt) métodos de tratamento de câncer, de células de câncer e de câncer resistente a antagonista de egfr, métodos de aumento da sensibilidade e da eficácia de tratamento de câncer e métodos de atraso, de tratamento de indivíduos com câncer e de extensão
WO2014145642A3 (en) Nrf2 small molecule inhibitors for cancer therapy
MX2016002645A (es) Tratamiento combinado para tratar el glioblastoma.
MX2015008685A (es) Tratamiento de artritis psoriasica usando apremilast.
MX2021001425A (es) Compuestos terapeuticos activos y sus usos.
EA201790913A1 (ru) Лечение заболеваний, связанных с активацией звездчатых клеток печени, с применением видов терапии, снижающих уровень аммиака
EA201591987A1 (ru) Лечение злокачественной опухоли дигидропиразинопиразинами
CA2908742C (en) Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
PH12016500863A1 (en) Tetracyclic autotaxin inhibitors
MX2017002364A (es) Terapia de combinacion para tratamiento de cancer.
MX2015011671A (es) Co-administracion de esteroides y acido zoledronico para prevenir y tratar la osteoartritis.
MX2015012444A (es) Metodos de diagnostico, seleccion y tratamiento de enfermedades y afecciones provocadas por o asociadas con metanogenos.
TW201612313A (en) Uses of ligustilide
MX2021011301A (es) Terapia combinada especifica contra tumores.
MX2015017505A (es) Lípidos estereoespecíficos para terapia locorregional con sistemas nanotransportadores que circulan a largo plazo sensibles a estímulos.
PH12020500472A1 (en) Autotaxin inhibitor compounds
UA88769U (uk) Спосіб профілактики та лікування доброякісних дисплазій молочних залоз у жінок з ранніми втратами вагітності
UA88729U (uk) Спосіб консервативного лікування хронічного геморою
UA107743C2 (ru) Способ лечения аденокарциномы
UA86338U (ru) Способ лечения беременных с гестационным диабетом